WINNIPEG, MANITOBA--(Marketwire - March 18, 2013) - Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, is pleased to announce it has appointed Pacific Veterinary Sales of Abbotsford, B.C. as a distribution partner for the upcoming StrixNB pet oral care product launch in Western Canada. On January 31, 2013 the company launched a marketing field test for StrixNB in Manitoba through veterinary clinics. The response in Manitoba has been exceptional with over 84% of the veterinary clinics signing up for the Company's promotional campaign and 61% of these clinics placing orders to regularly carry StrixNB in their clinics.

"Preparations for the launch into Western Canada are well underway and appointing distribution is an important step for this market of over 1200 veterinary clinics," stated Gord Froehlich, President and CEO of Kane Biotech. "Since announcing the market field test in Manitoba our team has been working diligently to prepare for this commercial introduction and have put key systems in place to meet the growing demand for StrixNB."

Pacific Veterinary Sales has a direct relationship with veterinarians through an established and dedicated sales team that focuses on veterinarians in Western Canada and will warehouse, distribute and sell StrixNB to the veterinary market.

"We are delighted to be working with Kane Biotech to launch their revolutionary new pet oral care product in Western Canada. Our committed core values of customer care specializing in sales and service of veterinary products, a great office team, and 60 dedicated staff are all excited to be part of the StrixNB launch," stated Ken Kasdorf, Director of Sales and Marketing. "We actively attend, sponsor and participate in veterinary conferences, trade shows and industry events and are eager to introduce StrixNB to all clinics from large clinic groups, dental specialists to smaller independent clinics."

About Pacific Veterinary Sales

Pacific Veterinary Sales is a privately held company established in 1981 and is an established and source of quality products in the veterinary distribution market for Western Canada. They have experienced strong growth over the last twenty years and have an established sales force that focuses on veterinarians in the three western provinces. They have Veterinary sales representatives on the road meeting with veterinarians, technicians and support staff in clinics/hospitals and built great relationships with these accounts.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Pure Advertising and Marketing
Kam Thindal

Kane Biotech Inc,
Gord Froehlich
President & CEO
204-453-1314 (FAX)